前立腺肥大症および下部尿路症状患者に対する選択的α1A受容体遮断薬（シロドシン）低用量投与の有効性に関する検討

The clinical efficacy of low-dose α1A-adrenoceptor-selective antagonist（sirodosin）on benign prostatic hyperplasia/lower urinary tract symptoms patients

　シロドシンは選択的α_1A受容体遮断薬である。その高い選択性から推察すると，少ない用量でも十分なα_1A受容体遮断効果が期待でき，安全性と経済性を向上できる可能性がある。われわれは，前立腺肥大症および下部尿路症状患者に通常用量と低用量のシロドシンを12週間投与し，その効果と安全性に関する検討を行った。その結果，国際前立腺症状スコア，QOL index，過活動膀胱症状スコア，1回排尿量，最大尿流率，平均尿流率，残尿量における治療効果の差を認めなかった。有害事象発現率は通常用量で33.3％，低用量で20.0％であった。シロドシン低用量投与は，十分なα_1A受容体遮断作用があり，安全性に優れた治療になり得る。

We investigated the clinical efficacy of low-dose administration of α_1A-adrenoceptor-selective antagonist（sirodosin）for clinically BPH/LUTS patients. 30 BPH/LUTS patients were equally separated into two groups,one treated with conventional-dose of sirodosin（8 mg/day）and the other with low-dose of sirodosin（2 mg/day）for 12 weeks. IPSS,QOL-index,OABSS,voided volume,Q_max,Q_ave,and post-voided residual urine were evaluated. After the treatment,in both groups all subjective data improved significantly and all objective data were slightly improved without statistical difference. However there were no statistical differences in all subjective and objective data between the two groups in each period. These results suggest that the efficacy of low-doze administration of sirodosin is equivalent to conventional-dose administration of sirodosin. Low-doze administration of sirodosin might be efficacious,safe,and cost-effective treatment for BPH/LUTS patients.